Development and characterization of a tamoxifen-resistant breast carcinoma xenograft
2000
Study of Tamoxifen-Resistant Breast Cancer
publication
Author Information
Author(s): Naundorf H, Becker M, Lykkesfeldt A E, Elbe B, Neumann C, Büttner B, Fichtner I
Primary Institution: Max-Delbrück-Center for Molecular Medicine
Hypothesis
What mechanisms contribute to tamoxifen resistance in breast cancer?
Conclusion
Tamoxifen-resistant breast cancer xenografts show altered hormone regulation and do not respond to tamoxifen treatment.
Supporting Evidence
- The tamoxifen-resistant line showed lower OR content compared to the sensitive line.
- Tamoxifen did not inhibit tumor growth in the resistant line.
- The resistant tumors lost regulation of pS2 and cathepsin D expression.
Takeaway
Researchers created a type of breast cancer that doesn't respond to a common treatment called tamoxifen, helping us understand why some cancers resist treatment.
Methodology
The study involved establishing a tamoxifen-resistant breast cancer model in mice and analyzing hormone receptor activity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website